The administration of GTE capsules containing 800 mg of EGCG seems to regulate biomarkers related to colorectal cancer pathogenesis, including selenoproteins, WNT signaling (β-catenin), inflammation (NF-κB), and methylation (DNMT1). This evidence concerns the gene DNMT1 and colorectal cancer.